Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Target |
Mechanism TRPV1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism COX inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism COX inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Jul 2023 |
Sponsor / Collaborator |
Start Date15 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
LASSBio-1018 ( COXs ) | Pain More | Preclinical |
LASSBio-365 ( TRPV1 ) | Cardiovascular Diseases More | Preclinical |
LASSBio-1181 ( COXs ) | Inflammation More | Preclinical |